People with rheumatoid arthritis will benefit from two new pieces of NICE guidance published today (25 August 2010). NICE recommends rituximab, adalimumab, etanercept, infliximab and abatacept , in certain circumstances, as possible treatments for rheumatoid arthritis after treatment with a tumour necrosis factor (TNF) inhibitor has failed. In separate guidance, NICE also recommends tocilizumab ...